Cargando…

Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer

INTRODUCTION: Delayed onset of immune‐related adverse events following immune‐checkpoint inhibitor discontinuation is underrecognized because of little available evidence. CASE PRESENTATION: A 50‐year‐old man with metastatic renal cell carcinoma (Case 1) and 58‐year‐old woman with renal cell carcino...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakai, Yasutomo, Otsuka, Tomoyuki, Inoue, Takako, Nawa, Takatoshi, Hatano, Koji, Yamamoto, Yoshiyuki, Nagahara, Akira, Nakayama, Masashi, Kakimoto, Ken‐ichi, Nishimura, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413213/ https://www.ncbi.nlm.nih.gov/pubmed/34497995 http://dx.doi.org/10.1002/iju5.12338

Ejemplares similares

Renal cell carcinoma with central nervous system demyelination caused by nivolumab
por: Oka, Toshiki, et al.
Publicado: (2020)

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
por: Yamamoto, Akinaru, et al.
Publicado: (2020)

Solitary fibrous tumor mimicking adrenal tumor concomitant with contralateral adrenal pheochromocytoma: A case report of surgical resection after long-term observation
por: Kuribayashi, Sohei, et al.
Publicado: (2019)

Partial nephrectomy for a Bosniak IV cystic renal mass mimicking a simple renal cyst adjacent to a solid renal tumor
por: Oka, Toshiki, et al.
Publicado: (2020)

Efficacy and safety of mycophenolate mofetil in treating immune‐related hepatitis induced by immune checkpoint inhibitor use: A retrospective study
por: Kadokawa, Yukio, et al.
Publicado: (2023)

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study
por: Kadokawa, Yukio, et al.
Publicado: (2021)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer
por: Kimura, Hideharu, et al.
Publicado: (2019)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report
por: Seo, Je Hyun, et al.
Publicado: (2022)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Whole-body MRI: detecting bone metastases from prostate cancer
por: Nakanishi, Katsuyuki, et al.
Publicado: (2021)

Androgen-Regulated Transcriptional Control of Sialyltransferases in Prostate Cancer Cells
por: Hatano, Koji, et al.
Publicado: (2012)

Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023)

Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma
por: Nishimura, Yuki, et al.
Publicado: (2022)

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report
por: Arigami, Takaaki, et al.
Publicado: (2020)

Editorial Comment on “Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment: A case report”
por: Hatano, Koji
Publicado: (2022)

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
por: Nakamura, Yoshiyuki, et al.
Publicado: (2021)

Computed tomography imaging findings of nivolumab-induced thyroid dysfunction
por: Oki, Tatsuya, et al.
Publicado: (2022)

The Vanguard of Community-based Integrated Care in Japan: The Effect of a Rural Town on National Policy
por: Hatano, Yu, et al.
Publicado: (2017)

Re: Long-term control in a patient with metastatic lung adenocarcinoma after discontinuation of nivolumab
por: Pampín-Sánchez, R, et al.
Publicado: (2021)

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors
por: Kawahara, Takashi, et al.
Publicado: (2022)

Distinct Roles of IL-1β and IL-18 in NLRC4-Induced Autoinflammation
por: Sasaki, Yuki, et al.
Publicado: (2020)

Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report
por: Antoniou, Sofia, et al.
Publicado: (2021)

A case of delayed exacerbation of interstitial lung disease after discontinuation of temsirolimus
por: Matsuki, Rei, et al.
Publicado: (2017)

Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab
por: MIYAMOTO, Shoko, et al.
Publicado: (2022)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report
por: Potluri, Lakshmi Bhavani, et al.
Publicado: (2023)

Blockade of the CXCR3/CXCL10 axis ameliorates inflammation caused by immunoproteasome dysfunction
por: Sasaki, Yuki, et al.
Publicado: (2022)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: continuous or discontinuous?
por: Nakayama, Takahisa, et al.
Publicado: (2010)

Editorial Comment from Dr Kojima to Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Kojima, Takahiro
Publicado: (2020)

Editorial Comment from Dr Yuasa to Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Yuasa, Takeshi
Publicado: (2020)

High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids
por: Yoshida, Takahiro, et al.
Publicado: (2015)

Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
por: Aoki, Yumi, et al.
Publicado: (2022)

Antimicrobials in the Hospital Are Unevenly Discontinued on Weekdays
por: Hagiya, Hideharu, et al.
Publicado: (2022)

EMMPRIN Promotes Angiogenesis, Proliferation, Invasion and Resistance to Sunitinib in Renal Cell Carcinoma, and Its Level Predicts Patient Outcome
por: Sato, Mototaka, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1u3t5oic6rqef009ej7o02cik9